Connection

Julio Lorenzi to Humans

This is a "connection" page, showing publications Julio Lorenzi has written about Humans.
Connection Strength

0.029
  1. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 2021 07; 595(7866):278-282.
    View in: PubMed
    Score: 0.002
  2. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021 05; 593(7859):424-428.
    View in: PubMed
    Score: 0.002
  3. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.002
  4. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis. 2021 02 13; 223(3):389-398.
    View in: PubMed
    Score: 0.002
  5. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 03; 591(7851):639-644.
    View in: PubMed
    Score: 0.002
  6. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Curr Opin HIV AIDS. 2021 01; 16(1):25-35.
    View in: PubMed
    Score: 0.002
  7. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.002
  8. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020 11 02; 217(11).
    View in: PubMed
    Score: 0.002
  9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 10 28; 9.
    View in: PubMed
    Score: 0.002
  10. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 08; 584(7821):437-442.
    View in: PubMed
    Score: 0.002
  11. Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):E11341-E11348.
    View in: PubMed
    Score: 0.002
  12. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 09; 561(7724):479-484.
    View in: PubMed
    Score: 0.002
  13. A non-functional galanin receptor-2 in a multiple sclerosis patient. Pharmacogenomics J. 2019 02; 19(1):72-82.
    View in: PubMed
    Score: 0.002
  14. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018 09 03; 215(9):2311-2324.
    View in: PubMed
    Score: 0.002
  15. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol. 2018 03 01; 92(5).
    View in: PubMed
    Score: 0.002
  16. Exome sequencing of multiple-sclerosis patients and their unaffected first-degree relatives. BMC Res Notes. 2017 Dec 12; 10(1):735.
    View in: PubMed
    Score: 0.001
  17. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell. 2017 Aug 10; 170(4):637-648.e10.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.